Search results for " Galliher"
Article
A Q&A With Parrish Galliher About Adopting Single-Use Systems
This week, Process Development Forum speaks with Parrish Galliher, Chief Technology Officer Upstream at Cytiva, about trends within the bioprocess area.
What’s one of the biggest t…
Article
Advanced Technologies Facilitate Scale-up and Technology Transfer
“Many of these processes were licensed long ago and are quite complex, contain open steps, and are inefficient in many places,” notes Parrish Galliher, CTO of BioProcess Upstream at Cytiva.
FDA has…
Article
Trends in Single-use Bioreactors
Participating in the roundtable are Jacob McNeil, senior product manager, single-use bioreactors at Thermo Fisher Scientific; Warren Ang, product manager, bioprocess at Eppendorf; Parrish Galliher, fo…
Article
Industry Adoption of Single-Use Systems Remains Low
…%, and the market growth has been reported to be around 20% in the past three years,” adds Parrish Galliher, chief technology officer of Upstream BioProcess at Cytiva’s Life Sciences division.
…
Article
Managing Biomanufacturing Capacity Expectations
It is more difficult to respond to shifting demands if process equipment and clean utility systems are hard piped into the infrastructure, says Parrish Galliher, CTO for upstream at Cytiva. Multiple c…
Article
Cell-Culture Advances Test Bioreactor Performance Models
The key to successful modeling for the prediction of bioreactor performance, stresses Galliher, is to first calculate the performance design space of the bioreactor at all relevant scales. “Once these…
Article
The New World of Biopharmaceutical Manufacturing
Industry experts discuss the single-use revolution and changes to upstream and downstream processing equipment.
By Jennifer Markarian
…
Article
Biopharma Says It Has an Evolution in New Technologies and Processes
Another challenge is maintaining sanitary conditions in a continuous process; the control of bioburden, while basic, is fundamental to success, said Galliher.
Implementing automation technology ca…
Article
Unifying Continuous Biomanufacturing Operations
Currently, approximately 20 FDA-approved biologic products are made using perfusion, according to a comment during INTERPHEX 2017 from Parrish Galliher, chief technology officer, upstream, at Cytiva. …
Article
A Q&A on Bioprocessing Trends and Technologies at INTERPHEX 2016
Parrish Galliher, chief technology officer, upstream, Cytiva, provided an overview of the KUBio facility and FlexFactory equipment at INTERPHEX.
Complexity and scale are two stumbling blocks to the…